# Study of the Efficacy and Safety of EPA in Patients With Type-2 Diabetes

Study · id `cardio:ct-nct06129526` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06129526](<https://clinicaltrials.gov/study/NCT06129526>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06129526

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 450 participants.

## Technical summary

Registry record NCT06129526. Randomized; double masking; primary purpose prevention. Start 2023-12 (anticipated); primary completion 2024-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 450 participants (planned count; ClinicalTrials.gov record NCT06129526, source copy `cardio:ctgov-nct06129526-2023-11-15`, retrieved 2026-10-26)
- Planned start: 2023-12 (anticipated) (ClinicalTrials.gov record NCT06129526, source copy `cardio:ctgov-nct06129526-2023-11-15`, retrieved 2026-10-26)
- Primary completion: 2024-09 (anticipated) (ClinicalTrials.gov record NCT06129526, source copy `cardio:ctgov-nct06129526-2023-11-15`, retrieved 2026-10-26)
- Completion: 2024-12 (anticipated) (ClinicalTrials.gov record NCT06129526, source copy `cardio:ctgov-nct06129526-2023-11-15`, retrieved 2026-10-26)
- Countries: Greece (ClinicalTrials.gov record NCT06129526, source copy `cardio:ctgov-nct06129526-2023-11-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06129526-2023-11-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of the Efficacy and Safety of EPA in Patients With Type-2 Diabetes
- Acronym: SEASIDE
- Condition: Diabetes Type 2
- Condition: Hypertriglyceridemia
- Condition: Diabetes Mellitus
- Intervention (Dietary supplement): EPAVasc
- Intervention (Dietary supplement): Corn Oil
- Lead sponsor: University of Ioannina
- Lead sponsor class: OTHER
- Collaborator: LIBYTEC Pharmaceutical S.A.
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: University of Ioannina (`cardio:org-university-of-ioannina`)

## Provenance

Content hash: b307f1135560cad4b7d92931758c26a15a29e6737d12c6874a1f4dc247156723
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
